|
May 14
|
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
|
|
May 13
|
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
|
|
May 2
|
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Apr 10
|
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
|
|
Mar 26
|
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
|
|
Mar 11
|
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
|
|
Mar 11
|
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
|
|
Mar 5
|
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
|
|
Jan 10
|
Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
|
|
Aug 10
|
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
|